KR101876304B1 - 뎅기 바이러스에 대한 백신 투여용 조성물 및 방법 - Google Patents

뎅기 바이러스에 대한 백신 투여용 조성물 및 방법 Download PDF

Info

Publication number
KR101876304B1
KR101876304B1 KR1020117031022A KR20117031022A KR101876304B1 KR 101876304 B1 KR101876304 B1 KR 101876304B1 KR 1020117031022 A KR1020117031022 A KR 1020117031022A KR 20117031022 A KR20117031022 A KR 20117031022A KR 101876304 B1 KR101876304 B1 KR 101876304B1
Authority
KR
South Korea
Prior art keywords
dengue virus
composition
subject
intradermal
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117031022A
Other languages
English (en)
Korean (ko)
Other versions
KR20120027396A (ko
Inventor
단 티. 스틴치콤
조지 이. 오소리오
카랄람보스 디. 파티도스
조셉 엔. 브레우
Original Assignee
다케다 백신즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101876304(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 백신즈 인코포레이티드 filed Critical 다케다 백신즈 인코포레이티드
Publication of KR20120027396A publication Critical patent/KR20120027396A/ko
Application granted granted Critical
Publication of KR101876304B1 publication Critical patent/KR101876304B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117031022A 2009-06-01 2010-05-28 뎅기 바이러스에 대한 백신 투여용 조성물 및 방법 Expired - Fee Related KR101876304B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01
US61/183,020 2009-06-01
PCT/US2010/036726 WO2010141386A1 (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Publications (2)

Publication Number Publication Date
KR20120027396A KR20120027396A (ko) 2012-03-21
KR101876304B1 true KR101876304B1 (ko) 2018-07-10

Family

ID=43220488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117031022A Expired - Fee Related KR101876304B1 (ko) 2009-06-01 2010-05-28 뎅기 바이러스에 대한 백신 투여용 조성물 및 방법

Country Status (17)

Country Link
US (2) US9211323B2 (cg-RX-API-DMAC7.html)
EP (1) EP2438198A4 (cg-RX-API-DMAC7.html)
JP (2) JP5848243B2 (cg-RX-API-DMAC7.html)
KR (1) KR101876304B1 (cg-RX-API-DMAC7.html)
CN (2) CN102449172A (cg-RX-API-DMAC7.html)
AU (3) AU2010256845B2 (cg-RX-API-DMAC7.html)
CA (1) CA2763944A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011003043A1 (cg-RX-API-DMAC7.html)
CO (1) CO6470882A2 (cg-RX-API-DMAC7.html)
CU (1) CU20110219A7 (cg-RX-API-DMAC7.html)
IL (2) IL216706A0 (cg-RX-API-DMAC7.html)
MX (1) MX343172B (cg-RX-API-DMAC7.html)
MY (1) MY184428A (cg-RX-API-DMAC7.html)
NZ (2) NZ618158A (cg-RX-API-DMAC7.html)
PH (1) PH12016502431A1 (cg-RX-API-DMAC7.html)
SG (1) SG176299A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010141386A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
CA3177574C (en) 2013-03-15 2026-03-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
JP2019511533A (ja) 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
CA3086456A1 (en) 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872553B1 (en) * 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
DK2278012T3 (en) 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
CA2755964C (en) 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
SG156666A1 (en) * 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
ZA200802176B (en) * 2005-08-10 2009-08-26 Acambis Inc Vaccination against dengue virus infection
DK2054428T3 (da) * 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
O'Hagan DT et al., Adv Drug Deliv Rev., Vol.58(1), pp.29-51. (온라인 공개 2006. 2. 9.) *
O'Hagan DT et al., Adv Drug Deliv Rev., Vol.58(1), pp.29-51. (온라인 공개 2006. 2. 9.)*

Also Published As

Publication number Publication date
EP2438198A4 (en) 2014-05-14
CN107913406A (zh) 2018-04-17
CA2763944A1 (en) 2010-12-09
US9211323B2 (en) 2015-12-15
EP2438198A1 (en) 2012-04-11
AU2016277660A1 (en) 2017-01-12
US20160129102A1 (en) 2016-05-12
WO2010141386A1 (en) 2010-12-09
NZ597000A (en) 2014-07-25
IL243204A0 (en) 2016-02-29
KR20120027396A (ko) 2012-03-21
JP2012528794A (ja) 2012-11-15
CO6470882A2 (es) 2012-06-29
IL216706A0 (en) 2012-02-29
JP2016033151A (ja) 2016-03-10
NZ618158A (en) 2015-05-29
AU2010256845A1 (en) 2011-12-22
CL2011003043A1 (es) 2012-07-20
JP5848243B2 (ja) 2016-01-27
PH12016502431A1 (en) 2019-02-11
US10010600B2 (en) 2018-07-03
CU20110219A7 (es) 2012-06-21
AU2010256845B2 (en) 2016-09-22
MY184428A (en) 2021-04-01
MX343172B (es) 2016-10-26
AU2019200212A1 (en) 2019-01-31
CN102449172A (zh) 2012-05-09
MX2011012807A (es) 2012-01-30
US20100303860A1 (en) 2010-12-02
SG176299A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
JP5848243B2 (ja) デングウイルスに対する免疫原性組成物
US8968996B2 (en) Compositions and methods for rapid immunization against dengue virus
Costa et al. DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus
JP2018090618A (ja) デングウイルスに対する免疫原性組成物およびワクチンキット
EP1896069B1 (en) Inactivated chimeric vaccines and related methods of use
JP6525984B2 (ja) デングウイルスワクチンのための方法および組成物
EP1645283A1 (en) Combination vaccine
Nielsen et al. DNA vaccines encoding proteins from wild-type and attenuated canine distemper virus protect equally well against wild-type virus challenge
AU2013339846A1 (en) Chimeric vaccine antigens against hepatitis C virus
EP1858548B1 (en) Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis
Wu et al. Induction of cross-protection against two wild-type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine
KR102243295B1 (ko) 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
WO2024118079A1 (en) Method for the prevention and treatment of coronavirus disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210704

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210704